Intermountain Blood and Marrow Transplant Program, LDS Hospital, Salt Lake City, Utah.
Intermountain Blood and Marrow Transplant Program, LDS Hospital, Salt Lake City, Utah.
Transplant Cell Ther. 2023 Jul;29(7):471.e1-471.e7. doi: 10.1016/j.jtct.2023.04.010. Epub 2023 Apr 21.
Diarrhea of other causes and Clostridioides difficile colonization are common in patients hospitalized for hematopoietic stem cell transplantation (HSCT). It has been well recognized that these issues tend to decrease the specificity of stool testing for C. difficile infection (CDI). The best way to address this problem is uncertain. In September 2018, we initiated a project with the goal of addressing the apparent problem of overdiagnosis of CDIs in our HSCT population. Using the quality improvement tool Model for Improvement, we introduced a C. difficile stool testing and CDI diagnosis algorithm with the aim of decreasing unnecessary inpatient CDI diagnoses and treatments. In this study, we examined the effects of the algorithm. We reviewed all HSCT admissions for the 2 years before introduction of the algorithm and the subsequent 3 years, recording all stool submissions for C. difficile determination and CDI. At the close of the study, we recruited our advanced practice providers (APPs) to review all CDIs following algorithm initiation and provide feedback on the ease of use of the algorithm and potential improvements to the overall process. Stool submissions for C. difficile determination decreased from 38.0/1000 to 20.6/1000 inpatient days (P < .001) and CDI diagnoses decreased from 5.5/1000 to 2.4/1000 days (P = .007). Patients admitted for a first allogeneic HSCT, first autologous HSCT, or HSCT readmission showed similar proportionate reductions. No detrimental effects on hospital length of stay, overall survival, progression-free survival, rate of readmission post-HSCT, incidence of acute graft-versus-host disease, or incidence of recurrent CDI were noted following algorithm introduction. A strategy of education, monitoring/feedback, and ease of algorithm access proved effective in inducing provider compliance. APPs rated the algorithm high on ease of use. We conclude that the use of an algorithm defining criteria for C. difficile testing, diagnosis, and treatment was associated with significantly decreased CDI diagnoses on a HSCT inpatient unit without apparent adverse effects.
其他原因引起的腹泻和艰难梭菌定植在因造血干细胞移植(HSCT)住院的患者中很常见。人们已经认识到,这些问题往往会降低粪便检测艰难梭菌感染(CDI)的特异性。解决这个问题的最佳方法尚不确定。2018 年 9 月,我们启动了一个项目,旨在解决我们 HSCT 人群中 CDI 过度诊断的明显问题。我们使用质量改进工具改进模型,引入了艰难梭菌粪便检测和 CDI 诊断算法,旨在减少不必要的住院 CDI 诊断和治疗。在这项研究中,我们检查了该算法的效果。我们回顾了引入该算法前 2 年和随后 3 年所有 HSCT 入院患者的记录,记录了所有用于确定艰难梭菌和 CDI 的粪便送检。在研究结束时,我们招募了我们的高级实践提供者(APPs),以审查所有在算法启动后的 CDI,并就算法的易用性以及对整个过程的潜在改进提供反馈。用于确定艰难梭菌的粪便送检量从 38.0/1000 降至 20.6/1000 住院日(P<0.001),CDI 诊断从 5.5/1000 降至 2.4/1000 天(P=0.007)。首次异基因 HSCT、首次自体 HSCT 或 HSCT 再入院的患者显示出相似的比例减少。在引入算法后,没有观察到对住院时间、总生存率、无进展生存率、HSCT 后再入院率、急性移植物抗宿主病发生率或复发性 CDI 发生率的不利影响。教育、监测/反馈和易于获取算法的策略被证明可以有效地诱导提供者遵守。APPs 对算法的易用性评价很高。我们的结论是,在 HSCT 住院病房中,使用定义艰难梭菌检测、诊断和治疗标准的算法与明显降低 CDI 诊断相关,而没有明显的不良反应。